The risk for obstructive lung disease was nearly 8 times greater in heavy stable smokers compared with never-smokers.
First bronchoscopic lung volume reduction using endobronchial valve performed at Temple University in Philadelphia, PA.
In patients with emphysema, deposition fraction was significantly lower than in other individuals, but no significant differences were found between healthy never smokers and current or former smokers.
After 2.1 years of follow-up, 49% of patients who had emphysema on chest CT were readmitted for heart failure and 24% had died.
The approval was based on results from a multicenter study (LIBERATE) of 190 patients with severe emphysema.
The clinical significance of emphysema was greater in people living with HIV vs those without HIV.
Zephyr® Endobronchial Valve EBV® treatment improved FEV1 in patients with heterogeneous emphysema.
Using e-cigarettes every day or some days increased the likelihood of developing chronic obstructive pulmonary disease.
Patients with chronic obstructive pulmonary disease with 5% emphysema based on thoracic computed tomography (CT) imaging may be at a greater risk for poor outcomes.
Independent predictive factors of lung cancer in chronic obstructive pulmonary disease may include frequency of exacerbations, in addition to airflow obstruction and visual emphysema.
Researchers used data from the Atherosclerosis Risk in Communities Study to assess associations between dietary pattern and pulmonary assessments.
Respiratory symptoms that develop between the ages of 18 and 30 may hold prognostic value for later decline in lung function.
Regular use of aspirin may slow the progression of emphysema.
A recent study examined whether nebulized glycopyrrolate is safe to use in patients with severe COPD and comorbid cardiovascular risk factors.
The safety of concurrently administering nebulized glycopyrrolate with long-acting beta agonists was examined in 3 studies.
Forced expiratory volume in 1 second and length of hospital stay were assess to determine the benefit of endobronchial valve placement vs standard of care in emphysema.
Advanced emphysema may benefit from endoscopic lung reduction treatment.
Higher doses were independently linked to slower change in emphysema, especially among former smokers
Treatment with full-dose angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers was found to slow disease progression in patients with emphysema.
Sunovion announces Utibron Neohaler, an inhalation powder for the long term maintenance treatment of airflow obstruction in COPD patients.